Pfizer Inc. (NYSE:PFE) Shares Bought by Zions Bancorporation N.A.

Zions Bancorporation N.A. lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 212,680 shares of the biopharmaceutical company’s stock after purchasing an additional 7,374 shares during the period. Zions Bancorporation N.A.’s holdings in Pfizer were worth $5,642,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the 4th quarter worth $28,000. Noble Wealth Management PBC purchased a new position in Pfizer during the 4th quarter worth $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the fourth quarter valued at $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.6 %

Shares of Pfizer stock opened at $26.13 on Tuesday. The company has a 50-day moving average of $26.15 and a two-hundred day moving average of $27.02. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $148.21 billion, a PE ratio of 18.53, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.